PRognostic factor of Early Death In phase II Trials or the end of ‘sufficient life expectancy’ as an inclusion criterion? (PREDIT model)
Crossref DOI link: https://doi.org/10.1186/s12885-016-2819-7
Published Online: 2016-10-04
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Grellety, Thomas
Cousin, Sophie
Letinier, Louis
Bosco-Lévy, Pauline
Hoppe, Stéphanie
Joly, Damien
Penel, Nicolas
Mathoulin-Pelissier, Simone
Italiano, Antoine
License valid from 2016-10-04